Lexicon Pharmaceuticals Statistics
Total Valuation
LXRX has a market cap or net worth of $719.37 million. The enterprise value is $468.72 million.
| Market Cap | 719.37M |
| Enterprise Value | 468.72M |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LXRX has 361.49 million shares outstanding. The number of shares has increased by 29.83% in one year.
| Shares Outstanding | 361.49M |
| Shares Change (YoY) | +29.83% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 1.15% |
| Owned by Institutions (%) | 72.83% |
| Float | 124.07M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 311.28 |
| Forward PS | 17.83 |
| PB Ratio | 2.49 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 202.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.58, with a Debt / Equity ratio of 0.36.
| Current Ratio | 15.58 |
| Quick Ratio | 15.26 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.93 |
Financial Efficiency
Return on equity (ROE) is -109.40% and return on invested capital (ROIC) is -47.21%.
| Return on Equity (ROE) | -109.40% |
| Return on Assets (ROA) | -62.50% |
| Return on Capital (ROIC) | -47.21% |
| Revenue Per Employee | $8,109 |
| Profits Per Employee | -$679,235 |
| Employee Count | 285 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.72% in the last 52 weeks. The beta is 1.36, so LXRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -8.72% |
| 50-Day Moving Average | 1.79 |
| 200-Day Moving Average | 1.72 |
| Relative Strength Index (RSI) | 56.87 |
| Average Volume (20 Days) | 2,969,506 |
Short Selling Information
The latest short interest is 20.20 million, so 5.59% of the outstanding shares have been sold short.
| Short Interest | 20.20M |
| Short Previous Month | 21.57M |
| Short % of Shares Out | 5.59% |
| Short % of Float | 16.28% |
| Short Ratio (days to cover) | 7.86 |
Income Statement
In the last 12 months, LXRX had revenue of $2.31 million and -$193.58 million in losses. Loss per share was -$0.83.
| Revenue | 2.31M |
| Gross Profit | 2.20M |
| Operating Income | -185.94M |
| Pretax Income | -193.58M |
| Net Income | -193.58M |
| EBITDA | -176.77M |
| EBIT | -177.35M |
| Loss Per Share | -$0.83 |
Balance Sheet
The company has $355.60 million in cash and $104.95 million in debt, giving a net cash position of $250.65 million or $0.69 per share.
| Cash & Cash Equivalents | 355.60M |
| Total Debt | 104.95M |
| Net Cash | 250.65M |
| Net Cash Per Share | $0.69 |
| Equity (Book Value) | 288.87M |
| Book Value Per Share | 0.80 |
| Working Capital | 341.25M |
Cash Flow
In the last 12 months, operating cash flow was -$185.41 million and capital expenditures -$222,000, giving a free cash flow of -$185.64 million.
| Operating Cash Flow | -185.41M |
| Capital Expenditures | -222,000 |
| Free Cash Flow | -185.64M |
| FCF Per Share | -$0.76 |
Margins
Gross margin is 94.98%, with operating and profit margins of -8,045.91% and -8,376.55%.
| Gross Margin | 94.98% |
| Operating Margin | -8,045.91% |
| Pretax Margin | -8,376.55% |
| Profit Margin | -8,376.55% |
| EBITDA Margin | -7,648.98% |
| EBIT Margin | -7,674.34% |
| FCF Margin | -8,032.71% |
Dividends & Yields
LXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -29.83% |
| Shareholder Yield | -29.83% |
| Earnings Yield | -26.91% |
| FCF Yield | -25.81% |
Analyst Forecast
The average price target for LXRX is $10.00, which is 402.51% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.00 |
| Price Target Difference | 402.51% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 248.54% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 21, 2015. It was a reverse split with a ratio of 1:7.
| Last Split Date | May 21, 2015 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
LXRX has an Altman Z-Score of -3.14 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.14 |
| Piotroski F-Score | 3 |